9 Meters Biopharma, Inc. (NMTRQ) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
4509 CREEDMOOR ROAD RALEIGH, NC 27612 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2023 MRQ | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 12,646 | 46,993 | 37,926 | 4,668 | 5,729 | 426 | |||
| Cash and cash equivalents | 12,646 | 46,993 | 37,926 | 4,668 | 5,729 | 426 | |||
| Restricted cash and investments | 17,013 | ||||||||
| Receivables | 90 | ||||||||
| Inventory, net of allowances, customer advances and progress billings | 101 | ||||||||
| Inventory | 101 | ||||||||
| Deferred costs | 105 | ||||||||
| Other undisclosed current assets | 3,359 | 2,992 | 1,001 | 555 | 580 | 46 | |||
| Total current assets: | 33,018 | 49,985 | 38,927 | 5,223 | 6,414 | 663 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 112 | 167 | 215 | 43 | ✕ | ✕ | |||
| Property, plant and equipment | 10 | 16 | 11 | 25 | 35 | ||||
| Deposits noncurrent assets | 14 | ||||||||
| Other noncurrent assets | 7 | 6 | 6 | 6 | 6 | ||||
| Total noncurrent assets: | 130 | 188 | 232 | 74 | 41 | 14 | |||
| TOTAL ASSETS: | 33,148 | 50,174 | 39,159 | 5,297 | 6,454 | 677 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 9,433 | 8,402 | 6,779 | 8,638 | 4,547 | 1,133 | |||
| Interest and dividends payable | ✕ | ✕ | 0 | 102 | |||||
| Accounts payable | 5,053 | 2,434 | 1,488 | 3,890 | 3,619 | 441 | |||
| Accrued liabilities | 4,380 | 5,968 | 5,290 | 4,748 | 826 | 692 | |||
| Debt | 19,616 | 14 | 3,227 | 5,197 | |||||
| Deferred compensation liability | 41 | ||||||||
| Derivative instruments and hedges, liabilities | 1,585 | 7 | 408 | 370 | |||||
| Customer refund liability | 125 | ||||||||
| Due to related parties | 33 | ||||||||
| Other undisclosed current liabilities | 62 | 55 | 49 | 2,597 | 1,359 | ||||
| Total current liabilities: | 30,696 | 8,457 | 6,848 | 14,911 | 10,113 | 2,650 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation: | 113 | 168 | |||||||
| Liabilities, other than long-term debt | 51 | ||||||||
| Operating lease, liability | 51 | 113 | 168 | ✕ | ✕ | ||||
| Other undisclosed noncurrent liabilities | (113) | (168) | |||||||
| Total noncurrent liabilities: | 51 | 113 | 168 | ||||||
| Total liabilities: | 30,747 | 8,570 | 7,016 | 14,911 | 10,113 | 2,650 | |||
| Equity | |||||||||
| Equity, attributable to parent | 2,401 | 41,603 | 32,142 | (9,614) | (3,659) | (1,973) | |||
| Common stock | 1 | 26 | 20 | 4 | 3 | 1 | |||
| Additional paid in capital | 215,006 | 210,418 | 164,183 | 60,947 | 39,854 | 38,039 | |||
| Accumulated deficit | (212,607) | (168,841) | (132,061) | (70,565) | (43,516) | (40,013) | |||
| Total equity: | 2,401 | 41,603 | 32,142 | (9,614) | (3,659) | (1,973) | |||
| TOTAL LIABILITIES AND EQUITY: | 33,148 | 50,174 | 39,159 | 5,297 | 6,454 | 677 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues (Revenue, Net) | 1,883 | |||||||
| Cost of revenue (Cost of Goods and Services Sold) | (1,947) | |||||||
| Gross profit: | (64) | |||||||
| Operating expenses | (42,017) | (36,762) | (60,878) | (25,549) | (18,224) | (8,888) | ||
| Other undisclosed operating income | 51,097 | 36,448 | ||||||
| Operating income (loss): | (42,017) | (36,762) | (60,878) | 25,549 | 18,224 | (8,952) | ||
| Nonoperating income (expense) | (1,749) | (17) | (619) | (1,500) | (5,938) | 1,027 | ||
| Investment income, nonoperating | 501 | |||||||
| Interest and debt expense | (20) | (47) | (4,046) | (1,049) | (6,152) | 200 | ||
| Income (loss) from continuing operations before equity method investments, income taxes: | (43,787) | (36,827) | (65,543) | 22,999 | 6,134 | (7,725) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | 20 | 47 | 4,046 | (50,048) | (30,296) | (200) | ||
| Loss from continuing operations: | (43,766) | (36,779) | (61,496) | (27,049) | (24,162) | (7,925) | ||
| Loss before gain (loss) on sale of properties: | ✕ | (36,779) | (61,496) | (27,049) | (24,162) | (7,925) | ||
| Net loss attributable to parent: | (43,766) | (36,779) | (61,496) | (27,049) | (24,162) | (7,925) | ||
| Other undisclosed net loss available to common stockholders, basic | (896) | |||||||
| Net loss available to common stockholders, diluted: | (43,766) | (36,779) | (61,496) | (27,049) | (24,162) | (8,821) | ||
Comprehensive Income ($ in thousands)
| 3/31/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (43,766) | (36,779) | (61,496) | (27,049) | (24,162) | (7,925) | ||
| Comprehensive loss, net of tax, attributable to parent: | (43,766) | (36,779) | (61,496) | (27,049) | (24,162) | (7,925) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.